Athira Pharma to Participate in Two Upcoming Investor Conferences

Rhea-AI Summary

Athira Pharma (NASDAQ: ATHA) announced participation in two major investor conferences. The first is the Stifel 2022 Virtual CNS Days on March 28-29 at 2:30 PM ET, featuring a fireside chat with key executives including Dr. Mark Litton and Dr. Hans Moebius. The second event is the 21st Annual Needham Virtual Healthcare Conference from April 11-14, with a presentation scheduled for April 14 at 3:00 PM ET. Live webcasts will be available on the Athira website, with recordings accessible for 30 days after.

BOTHELL, Wash., March 21, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that members of Athira Pharma’s senior management team will participate in the following upcoming investor conferences.

Stifel 2022 Virtual CNS Days – March 28-29, 2022
Date/Time:	March 28, 2022 at 2:30 pm Eastern time
Format:	Fireside Chat
Moderator:	Paul Matteis, Managing Director, Biotechnology Equity Research at Stifel
Presenters:	Mark Litton, Ph.D., President & CEO, Hans Moebius, M.D., Ph.D., Chief Medical Officer, Rachel Lenington, Chief Operating Officer

21st Annual Needham Virtual Healthcare Conference – April 11-14, 2022
Date/Time:	April 14, 2022 at 3:00 pm Eastern time
Format:	Fireside Chat
Moderator:	Ami Fadia, Managing Director, Senior Biotechnology Equity Research Analyst at Needham & Co.
Presenters:	Mark Litton, Ph.D., President & CEO, Hans Moebius, M.D., Ph.D., Chief Medical Officer, Rachel Lenington, Chief Operating Officer

A live webcast of each fireside chat can be accessed from the Investors section of the Athira website at https://investors.athira.com/news-and-events/events-and-presentations. An archived replay of the webcast will be available for at least 30 days following the event.

About Athira Pharma, Inc.
Athira Pharma, Inc., headquartered in the Seattle area, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration. Athira aims to provide rapid cognitive improvement and alter the course of neurological diseases with our novel mechanism of action. Athira is currently advancing its lead therapeutic candidate, fosgonimeton (ATH-1017), a novel small molecule for Alzheimer’s and Parkinson’s disease dementia and Dementia with Lewy bodies. For more information, visit www.athira.com. You can also follow Athira on Facebook, LinkedIn and @athirapharma on Twitter and Instagram.

Investor & Media Contact:
Julie Rathbun
Athira Pharma
Julie.rathbun@athira.com
206-769-9219

FAQ

What are the details of Athira Pharma's participation in the Stifel 2022 Virtual CNS Days?

Athira Pharma will participate in the Stifel 2022 Virtual CNS Days on March 28-29, 2022, with a fireside chat scheduled for March 28 at 2:30 PM ET.

When is Athira Pharma's presentation at the Needham Virtual Healthcare Conference?

Athira Pharma will present at the 21st Annual Needham Virtual Healthcare Conference on April 14, 2022, at 3:00 PM ET.

Who are the key presenters for Athira Pharma at the upcoming investor conferences?

The key presenters include Dr. Mark Litton, Dr. Hans Moebius, and Rachel Lenington.

Where can I watch the live webcasts of Athira Pharma's presentations?

The live webcasts can be accessed on the Investors section of Athira's website.

How long will the webcasts of the investor conferences be available for viewing?

The archived replays of the webcasts will be available for at least 30 days following the events.